LENZ Therapeutics Inc (LENZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has a cash flow conversion efficiency ratio of -0.116x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.02 Million) by net assets ($284.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LENZ Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
LENZ Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how LENZ Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LENZ Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LENZ Therapeutics Inc ranked by their cash flow conversion efficiency. See LENZ Therapeutics Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tectonic Metals Inc
V:TECT
|
-0.483x |
|
Endomines Finland Oyj
HE:PAMPALO
|
0.142x |
|
Affinity Bancshares Inc
NASDAQ:AFBI
|
0.034x |
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
-0.327x |
|
Korvest Ltd
AU:KOV
|
0.045x |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
0.002x |
|
D-Box Technologies Inc.
TO:DBO
|
0.058x |
|
Wellcall Holdings Bhd
KLSE:7231
|
0.003x |
Annual Cash Flow Conversion Efficiency for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of LENZ Therapeutics Inc from 2019 to 2025. View LENZ Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $284.34 Million | $-69.17 Million | -0.243x | +16.41% |
| 2024-12-31 | $204.08 Million | $-59.39 Million | -0.291x | -144.68% |
| 2023-12-31 | $-92.71 Million | $-60.38 Million | 0.651x | -82.11% |
| 2022-12-31 | $-24.17 Million | $-87.98 Million | 3.640x | -2.10% |
| 2021-12-31 | $-14.21 Million | $-52.85 Million | 3.718x | +317.84% |
| 2020-12-31 | $-9.80 Million | $-8.72 Million | 0.890x | +10288.39% |
| 2019-12-31 | $-2.22 Million | $-19.00K | 0.009x | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more